Novo Nordisk A/S (NYSE: NVO) is trading at an 85 percent premium to Morningstar’s fair value estimate of $18.00 per share, with the stock sitting around $40 to $41, making it one of the most starkly overvalued large-cap pharmaceutical names in the research firm’s coverage universe despite the ongoing collapse in NVO’s share price from its all-time high.
That apparent contradiction, a stock down more than 50 percent from peak yet still 85 percent above intrinsic value, captures the scale of how dramatically Novo Nordisk was mispriced by the market at the height of GLP-1 euphoria in 2024.
Morningstar’s analysis of Novo heading into the May 7 earnings report focuses on three interconnected questions that will shape the company’s trajectory through the rest of 2026 and beyond.
The first is the Wegovy pill’s commercial performance in the United States, where early prescription data since the oral formulation’s launch has been described as promising but where the direct-to-patient channel remains a gap relative to Eli Lilly’s Zepbound platform.
Orforglipron, Eli Lilly’s (NYSE: LLY) oral GLP-1 drug, arrived on the market in April and represents the first genuinely comparable competitive threat to the Wegovy pill in the same delivery format, increasing pressure on Novo to demonstrate superior efficacy, tolerability, or access advantages that justify co-prescription alongside or ahead of Lilly’s product.
Morningstar assumes US semaglutide prices could fall more than 20 percent in 2026, an acceleration beyond their prior assumption, driven by Medicare Part D negotiations on Ozempic and Rybelsus beginning in 2027 and compounded by competition from authorised generics and compounders operating at the edges of the regulated market.
Despite these headwinds, Morningstar assigns Novo a Wide economic moat rating, reflecting strong intangible assets in diabetes and cardiometabolic disease, a focused research and development strategy that repeatedly extends patent protection through innovation, and manufacturing scale and efficiency that give the company structural cost advantages in its core insulin business.
The Exemplary Capital Allocation rating Morningstar maintains recognises Novo’s sound balance sheet, strong free cash flows, and its stated commitment to both internal pipeline investment and shareholder distributions through dividends, all of which provide financial flexibility during the current period of competitive pressure.
Wall Street’s broader consensus on NVO diverges sharply from Morningstar’s bearish valuation, with six analysts maintaining a Buy rating and a consensus price target of approximately $57.92 as of May 1, reflecting a view that the GLP-1 market’s long-term growth trajectory more than compensates for the near-term pricing and competitive headwinds.
The May 7 report will provide the first formal data point on how Wegovy pill uptake, Ozempic pricing, and the Rybelsus competitive dynamics are actually playing out in Q1 2026, with management’s full-year guidance commentary likely carrying more market-moving weight than any individual revenue or earnings line given the unprecedented uncertainty surrounding the company’s near-term commercial outlook.
Ewan is a reporter at the Foreign Policy Journal, primarily covering US current affairs and news related to NYSE-listed stocks. He has over two decades of experience in journalism and digital publishing.
